Sun Pharmaceutical Industries will extend Most Favoured Nation (MFN) pricing to state medicaid programmes of the U.S. It has also committed to MFN pricing for future innovative medicine launches.

The announcement followed a White House ceremony on August 31, in which the U.S. government signed agreements with nine pharmaceutical companies, including Sun Pharma, aimed at improving access to affordable medicines for millions of Americans.

Sun Pharma said the agreement recognises its investment in the U.S. market by delaying Section 232 tariffs on innovative pharmaceutical products for over two years. Further terms of the agreements remain confidential, the company said.

“The United States is a key area of investment and expansion for Sun Pharma across clinical development, sales and marketing, and both API and finished products manufacturing. We are proud to play our part in delivering the medicines that millions of American patients count on every day,” said Rick Ascroft, North America CEO, Sun Pharma, who represented the company at the White House.

The company said it built its U.S. presence on a foundation of high-quality generic medicines, followed by an increasing focus on innovative and specialty products. It ranks second in the U.S. by prescriptions in dermatology and continues to expand its presence across dermatology and immunology, cutaneous oncology, and ophthalmology. These businesses complement its strong portfolio of consumer health products and generics.

The U.S. is the company’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue. Earlier this year, Sun Pharma signed a definitive agreement to acquire Organon & Co in a deal valued at $11.75 billion.

The White House said the nine new agreements are part of President Donald Trump’s initative to lower prescription drug prices for Americans in line with the lowest prices paid by other developed nations (known most-favoured-nation price). With the latest agreements, 26 pharmaceutical manufacturers now have signed MFN deals, covering 89% of the branded drug market.

Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB are the nine manufacturers.

The agreements will provide every State Medicaid programme in the country access to MFN drug prices on products made by the nine companies, resulting in billions of dollars in savings for Americans.

The nine manufacturers have committed to invest at least $19.6 billion collectively in U.S. manufacturing in the near term. Additionally, as part of the agreements, several companies are donating active pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign nations and ensure the U.S. has an adequate supply of such products in the event of an emergency, the White House said.

Sun Pharma will contribute 71.4 tonnes of clindamycin and 6.75 tonnes of doxycycline — both antibiotics — to the SAPIR.

Medicaid is jointly funded by States and the federal government in the U.S. and provides health coverage to millions of Americans, including eligible low-income adults, children, pregnant women, elderly adults and people with disabilities.

Sun Pharmaceutical Industries on Monday (August 17, 2026) said an appellate court in the United States has passed a judgment in favour of the company and its subsidiaries in the antitrust litigation, in the U.S., relating to a 2008 patent litigation settlement agreement with Pfizer concerning generic Lipitor (Atorvastatin).

The United States Court of Appeals for the Third Circuit has affirmed the order of the United States District Court granting summary judgment in its entirety in favour of the company and its subsidiaries. The appellate court has also affirmed the District Court’s orders denying class certification as to the plaintiffs, the generic drugmaker said.

“This decision represents a significant favourable development for the company and its subsidiaries in the matter, and brings the litigation substantially to a close, subject to any further remedies that may be available to the plaintiffs under applicable law,” it said.

The plaintiffs, in the antitrust litigation, had alleged the settlement agreement with Pfizer unlawfully delayed generic competition for Lipitor.

Sun Pharmaceutical Industries has received Brazilian Health Regulatory Agency ANVISA approval to manufacture and market semaglutide injection in the Latin American country.

The generic drugmaker plans to launch the product in the next few days in partnership with Hypera Pharma, a pharmaceutical company in Brazil. It will be available as a pre‑filled, multi‑dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) allowing flexible, once‑weekly dosing.

“The approval of semaglutide in Brazil expands access to an evidence-based treatment option for people living with inadequately controlled type 2 diabetes. It reflects the strength of our development and manufacturing capabilities,” said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.

The semaglutide injectable market in Brazil is around $413 million, Sun Pharma said citing IQVIA, MAT June 2026 data.

Earlier this month, Sun Pharmaceutical launched generic semaglutide in South Africa following approval from the regulator in the country. The product is supplied in a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible, once-weekly dosing, the company said. South Africa was the second market where it had launched the product, after India.

Sun Pharma was among a clutch of generic drugmakers that launched semaglutide following patent expiry in March, in India. Semaglutide is the active ingredient in Novo Nordisk’s blockbuster diabetes and weight loss drugs Wegovy and Ozempic.

Sun Pharma getting Brazil’s approval comes on the heels of competitor Dr. Reddy’s recently halting commercial supplies of its generic semaglutide after an issue associated with the active pharmaceutical ingredient (API) used in the drug and fresh despatches were likely to resume only towards late October or early November. The development is bound to affect customers in India and Canada, said Dr. Reddy’s. The Hyderabad-based generic drugmaker was also eyeing Brazil for its semaglutide.